Andrew H. Wei

Research Statement

AI generated · 1d ago

Andrew H. Wei's research centres on optimizing venetoclax-based regimens for acute myeloid leukemia, particularly in patients unfit for intensive chemotherapy. His phase 3 trial of venetoclax plus low-dose cytarabine in newly diagnosed AML (762 citations) and an earlier phase Ib/II study of the same combination (688 citations) established this doublet as a practice-changing option, while his senior-author analysis of molecular patterns of response and treatment failure after frontline venetoclax combinations (678 citations) probed why some patients relapse. Related work extends to oral azacitidine maintenance in first remission and to co-targeting MCL-1 alongside BCL-2. Beyond these, Wei contributed to the 2017 and 2022 ELN recommendations for diagnosis and management of AML in adults and to the International Consensus Classification of myeloid neoplasms and acute leukemias, both widely used reference frameworks, and to trials of midostaurin in FLT3-mutated AML and blinatumomab in advanced ALL. No software, datasets, patents, or grants are indexed beyond his publications. Collectively, the named works trace a line from preclinical BH3-mimetic biology to consensus guidelines and late-phase trials.

Most Cited Works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Richard A Larson, Ross L Levine, Francesco Lo-Coco, Tomoki Naoe, Dietger Niederwieser, Gert J Ossenkoppele, Miguel Sanz, Jorge Sierra, Martin S Tallman, Hwei-Fang Tien, Andrew H Wei, Bob Löwenberg, Clara D Bloomfield

Blood2016

5,776Citations

Research Areas

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular proceCancer, Lipids, and MetabolismFerroptosis and cancer prognosisChronic Myeloid Leukemia Treatments

Affiliations & Education

Education

2005–present· now
The University of Melbourne(AU)
PhD · Medical Biology

Employment

2022–present· now
Walter and Eliza Hall Institute of Medical Research(AU)
Laboratory head · Division of Blood Cells and Blood Cancer
2022–present

Loading ORCID activity...

Sources

Research Statement

Most Cited Works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Research Areas

Affiliations & Education

Education

Employment

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation